Pacira's EXPAREL Patent Status and Litigation in 2026
Pacira Biosciences' EXPAREL (bupivacaine liposome injectable suspension) is currently involved in patent litigation, with key patents facing challenges that could impact its market exclusivity leading up to and beyond 2026 [1]. The primary concern for Pacira is the potential for generic competition once these patents expire or are successfully invalidated.
What Patents Are Key to EXPAREL's Protection?
The patent portfolio for EXPAREL includes several patents related to its composition of matter, methods of use, and manufacturing processes. The United States Patent No. 7,402,571, which covers the bupivacaine liposome injectable suspension itself, has been a central focus of recent litigation [1]. Other patents may cover specific formulations or delivery methods.
How Are EXPAREL's Patents Being Challenged?
Generic manufacturers have challenged the validity of key EXPAREL patents through inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) and through district court litigation. These challenges often argue that the challenged claims are obvious in light of prior art or lack sufficient novelty [1].
What is the Current Litigation Status for EXPAREL Patents?
The litigation surrounding EXPAREL's patents is ongoing and complex, with decisions in district courts and at the USPTO impacting the timeline for potential generic entry. Pacira has faced some setbacks in these legal battles, with certain patent claims being invalidated in IPR proceedings [1].
When Does EXPAREL's Main Patent Protection Expire?
While the exact expiration dates for all patents can vary and are subject to ongoing litigation and potential extensions, the '571 patent, which has been a cornerstone of EXPAREL's protection, has faced challenges that could influence its effective market exclusivity timeline. DrugPatentWatch.com tracks these developments, indicating that the expiration of key patent protections is a significant factor in assessing future market dynamics for EXPAREL [1].
Could Generic EXPAREL Be Available Before Patent Expiry?
The outcome of current patent litigation, particularly the success of IPR challenges, could potentially lead to earlier generic entry than originally anticipated based on stated patent expiration dates. If patents are invalidated, generic manufacturers may seek to launch their products sooner [1].
What Are the Potential Impacts of Generic Competition?
The introduction of generic versions of EXPAREL would likely lead to increased price competition, potentially reducing revenue for Pacira Biosciences. It would also offer more treatment options for patients and healthcare providers at a lower cost [1].
How Does EXPAREL Function?
EXPAREL is a non-opioid analgesic that utilizes proprietary DepoPharm™ technology to provide prolonged local analgesia. It works by encapsulating bupivacaine in a lipid-based particle (liposome), which slowly releases the anesthetic over time, thereby reducing the need for systemic opioids and repeated dosing of short-acting local anesthetics [2].
What are the Clinical Uses of EXPAREL?
EXPAREL is indicated for preventive analgesia in patients undergoing surgery and is used for controlling post-operative pain. Its long-acting nature aims to manage pain for extended periods following a single administration, reducing the overall burden of pain management for patients [2].
What is the Competition for EXPAREL?
Beyond generic competition, EXPAREL faces competition from other long-acting local anesthetics and regional anesthesia techniques. These alternatives may offer different durations of action, cost profiles, or administration methods, influencing physician and patient choice [2].
Sources:
[1] DrugPatentWatch.com
[2] Pacira Biosciences, Inc.